SCHEMBL6718315

SCHEMBL6718315

COc1ccc([N+](=O)[O-])cc1NC(=S)NC(C(=O)Nc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.63
KMT2A Q03164 10/20 0.63
MAPT P10636 7/20 0.63
LMNA P02545 6/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
ALDH1A1 P00352 4/20 0.63
HTT P42858 2/20 0.63
POLB P06746 2/20 0.58
MAPK1 P28482 2/20 0.58
HPGD P15428 1/20 0.55
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
TP53 P04637 1/20 0.53
BLM P54132 1/20 0.51
KDM4E B2RXH2 1/20 0.49
CYP2C9 P11712 1/20 0.49
PYGL P06737 1/20 0.49
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726499 0.94 ALDH1A1 (0.67) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6715791 0.93 ALDH1A1 (0.63) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6726682 0.93 ALDH1A1 (0.65) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL8328720 0.92 ALDH1A1 (0.64) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6718096 0.92 MEN1 (0.64) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6719997 0.92 MEN1 (0.64) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6719096 0.91 MEN1 (0.67) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6722727 0.91 ALDH1A1 (0.63) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6726536 0.89 MEN1 (0.61) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6719603 0.89 ALDH1A1 (0.60) MEN1KMT2AMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MEN1 2822/4885KMT2A 1656/4885MAPT 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.